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Introduction: Discovering non-invasive and easily acquired biomarkers that are con-
ducive to the accurate diagnosis of dementia is an urgent area of ongoing clinical
research. One promising approach is retinal imaging, as there is homology between
retinal and cerebral vasculature. Recently, optical coherence tomography angiography
(OCT-A) has emerged as a promising new technology for imaging themicrovasculature
of the retina.
Methods:A systematic review andmeta-analysis was conducted to examine the appli-
cation of OCT-A in dementia.
Results:Fourteen studies assessingOCT-A inpreclinicalAlzheimer’s disease (AD),mild
cognitive impairment, or ADwere included. Exploratory meta-analyses revealed a sig-
nificant increase in the foveal avascular zone area and a significant decrease in super-
ficial parafoveal andwhole vessel density in AD, although therewas significant hetero-
geneity between studies.
Discussion: Although certain OCT-A metrics may have the potential to serve as
biomarkers for AD, the field requires further standardization to allow conclusions to
be reached regarding their clinical utility.
KEYWORDS
Alzheimer’s disease, dementia, diagnostic tool, foveal avascular zone, mild cognitive impairment,
optical coherence tomography angiography, perfusion density, preclinical, retinal imaging, retinal
vasculature, vessel density
1 INTRODUCTION
Alzheimer’s disease (AD) andother formsof dementia are rising rapidly
in prevalence and subsequently pose growing challenges to individu-
als and families as well as to societal and healthcare systems globally.1
As such, discovering non-invasive biomarkers that can be measured
objectively and that are conducive to effective screening and diagno-
sis of dementia is an urgent area of clinical research.2 Within the dis-
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any
medium, provided the original work is properly cited, the use is non-commercial and nomodifications or adaptations aremade.
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ease continuum, thepathological processesof dementia arebelieved to
begin years before signs of cognitive symptoms appear.3 In particular,
AD pathology is characterized by the formation of extracellular amy-
loid beta (Aβ) plaques and intracellular neurofibrillary tangles of hyper-
phosphorylated tau, as well as changes to the cerebral vasculature
such as cerebral amyloid angiopathy, atherosclerosis and arterioscle-
rosis, reduced capillary density, and altered capillary morphology.4–7
It has been shown that Aβ plaque deposition is almost at its peak by
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the time cognitive symptomsmanifest, whereas the acceleration of tau
tangle accumulation may mark the transition period from the preclini-
cal stage to clinically detectable symptoms, after which those affected
often experience a period of mild cognitive impairment (MCI) before
progressing to AD.8,9 However, the effects of Aβ and tau deposition on
synaptic dysfunction and neuronal survival do not peak until moder-
ate to severe stages are reached.10 Thus early intervention is of utmost
importance for developing and administering preventive therapies for
AD that preserve cognitive abilities or delay decline.
Due to the shared diencephalic origin of the retina and brain, there
is homology between retinal and cerebral vasculature, and the retina is
thus regarded as an extension of the central nervous system (CNS).11
Some CNS disorders, such as cerebral small vessel disease and AD,
are accompanied by ocular manifestations that reflect changes occur-
ring in the brain.12–15 For example, retinal microvascular changes such
as venular dilation are observed with cerebral small vessel disease,16
and narrow venular caliber and increased venular tortuosity have been
observed in AD.17 Changes tometrics that quantify aspects of the reti-
nal microvasculature, such as reduced venous blood flow rate, may
even be seen in earlier stages of disease.18
Although cerebrovascular imaging is often expensive and requires
the use of specialized techniques such as positron emission tomogra-
phy (PET), retinal imaging provides an opportunity for a non-invasive
and quick modality to diagnose dementia or identify a need for early
intervention.19 Previous systematic reviews and meta-analyses have
been conductedon theuseof retinal imaging techniques suchasoptical
coherence tomography (OCT) and fundus photography as sources of
biomarkers for dementia.20,21 Recently, OCT angiography (OCT-A) has
emerged as a promising new technology for imaging the retina, which
builds on established OCT technology and provides high-resolution
imagesof the retinalmicrovasculature and choroid.22 Previous reviews
have reported on the uses of OCT-A in neurological research.23–25
However, to the best of our knowledge, our review constitutes the first
meta-analytic approach to explore the use ofOCT-Ametrics in demen-
tia. We gave consideration to the different metrics that various stud-
ies featuring OCT-A and persons with dementia have reported, andwe
aimed, where possible, to compare quantitatively across studies and
highlight agreements or differences in their outputs. Furthermore, we
propose several methods of standardization that may improve compa-
rability among future studies.
2 METHODS
2.1 Search strategy
Studieswere identified through systematic searches of theMedical Lit-
erature Analysis and Retrieval System Online (MEDLINE, from 1966),
PubMed (from 1946), and the Excerpta Medica Database (EMBASE,
from 1980) for all studies published through August 2020, in all
languages. The search terms were “optical coherence tomography
angiography” with “dementia” or “Alzheimer” or “Lewy body disease”
or “vascular dementia” or “frontotemporal dementia” or “small vessel
HIGHLIGHTS
∙ Most studies using optical coherence tomography angiog-
raphy (OCT-A) metrics in dementia have focused on
Alzheimer’s disease (AD)
∙ Changes in the foveal avascular zone (FAZ) area and super-
ficial vessel density may reflect AD progression
∙ Standardization is needed before meaningful conclusions
can be drawn
RESEARCH INCONTEXT
1. Systematic review: The authors reviewed the litera-
ture using MEDLINE, PubMed, EMBASE, and Google
Scholar. We identified 14 studies using the optical
coherence tomography angiography imaging modality to
assess changes in the retinal microvasculature along the
Alzheimer’s disease continuum.
2. Interpretation: Although our findings suggest that mea-
surements of the foveal avascular zone area and vessel
density of the superficial retinal layer may hold promise
as potential biomarkers for Alzheimer’s disease, method-
ological standardization is required before studies can be
meaningfully compared and conclusions drawn as to the
clinical utility of these novel metrics.
3. Future directions: We propose several steps to stan-
dardize future studies conducted in this area. Examples
include: (a) reaching a consensus on terminology and
anatomical boundaries used to describe and define mac-
ular and optic disc regions of study; (b) stratification
of stages along the Alzheimer’s disease continuum; (c)
standardization of ophthalmological imaging protocols;
and (d) standardization of vessel density calculation algo-
rithms.
disease” or “mild cognitive impairment” or “cognitive” or “cognition” or
“memory.” A forward citation search was also conducted using Google
Scholar, although no further studies were identified.
2.2 Inclusion and exclusion criteria
This review aimed to include all published studies utilizing OCT-A to
examine the association between the retinal microvasculature and any
stage of dementia, including the preclinical stage. In this review, we
defined preclinical dementia as the stage at which biomarkers, for
example, Aβ+ or tau+ for preclinical AD, are present, but cognition or
the ability to perform activities of daily living are not yet impaired.26,27
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Inclusion criteria were (1) original study that had undergone peer
review; (2)written inEnglish; (3) inclusionof retinalmicrovascularmet-
rics using OCT-A; (4a) diagnosis of any form of dementia based on
established criteria such as that of the National Institute on Aging and
Alzheimer’s Association (NIA-AA) or the National Institute of Neuro-
logical, Communicative Disorders and Stroke-Alzheimer Disease and
Related Disorders Association (NINCDS-ADRDA)28,29 or (4b) diagno-
sis of preclinical dementia by biomarker status, for example, Aβ+ or
tau+; and (5) inclusion of a control group. Exclusion criteria were (1)
reviews; (2) case reports; (3) non-human research; (4) non–English-
language studies; (5) conference presentations or summaries; (6) stud-
ies without details of diagnostic criteria; (7) studies without OCT-A;
and (8) studies without a control group.
2.3 Data extraction
The identified studies were screened by title and abstract for duplica-
tion and relevance. The remaining studies were then subjected to full-
text review, and inclusion and exclusion criteria were applied (Supple-
mentary Figure S1). Data extracted were: (1) title; (2) first author; (3)
year of publication; (4) study aim; (5) study design; (6) number of par-
ticipants; (7) mean age; (8) diagnostic criteria; (9) participant selection
criteria; (10)methodof imaging and analysis used; (11) results; and (12)
conclusions.
2.4 Statistical analysis
Study-specific OCT-A measurement results are reported as mean
difference (MD) with a P-value for significance. Meta-analyses of con-
tinuous outcomes were conducted with Review Manager Software
Version 5.3 (Cochrane, Oxford)30 using an inverse variance (IV)
random-effects model to calculate summary estimates of mean dif-
ference from extracted means, standard deviations (SDs), and sample
sizes (Total) with 95% confidence intervals (CIs). Heterogeneity was
tested using a χ2 test with a significance threshold of P < 0.05. Anal-
yses stratified by disease stage subgroups (ie, preclinical AD, MCI, AD)
were conductedwhere possible.
3 RESULTS
The literature search yielded 177 results, of which 53 were unique
studies. Of these, 34 were removed after they were determined to not
meet the inclusion/exclusion criteria after a title and abstract screen.
The full-text versions of the remaining 19 studies were retrieved. One
study was omitted as it mentioned OCT-A in the abstract but not else-
where in the article. One studywas omitted because it lacked a control
group. Two studies were omitted because they did notmeet the appro-
priate diagnostic criteria, for example, if onlyMiniMental State Exami-
nation (MMSE) scores were used. A final study was omitted because it
was the only study featuring cerebral autosomal dominant arteriopa-
thy with subcortical infarcts and leukoencephalopathy (CADASIL) and
would thus not make for a suitable comparison with the other studies
(all of which featured preclinical AD, MCI, or AD). See Supplementary
Figure S1 for a flow diagram of the paper selection process. The popu-
lations sampled were from the United States (5), The Netherlands (2),
Italy (2), Germany (1), Poland (1), Turkey (1), SouthKorea (1), andChina
(1). Table 1 describes the final set of 14 studies.
3.1 Study design and population
All included studies were observational, 13 of which were case-
control studies31–43 and one of which was a case-control, population-
based study44 (Table 1). Some studies also described a prospective
design,34,36–38,41,42 although no longitudinal results have been pub-
lished at the time of this review. The number of unique participants
across all studies was 942. The number of participants with AD ranged
from 12 to 48, the number of participants with MCI ranged from 12 to
37, and thenumber of participantswith preclinical AD ranged from7 to
14among studies. Theaverageageof participantswithADranged from
65.4 to 74.2 years, the average age of participants with MCI ranged
from67.8 to 76.3 years, the average age of participantswith preclinical
AD ranged from 68.6 to 82.4 years, and the average age of control par-
ticipants ranged from 60.6 to 76.3 years. Studies defined AD as meet-
ing NIA-AA criteria,31,33,34,36,39 meeting NINCDS-ADRDA criteria,38
or meeting NIA-AA criteria and Aβ/tau+ confirmed through cere-
brospinal fluid (CSF) analysis or amyloid positron emission tomography
(amyloid-PET).29,32,40 Studies defined MCI as MCI meeting NIA-AA
criteria,33,36,39 amnestic MCI (aMCI) meeting NIA-AA criteria,43 aMCI
or early stage AD (eAD) meeting NIA-AA criteria,41 or MCI meeting
Petersen criteria.29,38,45 One study described an Alzheimer’s disease–
related cognitive impairment (ADCI) group, which combined AD and
aMCImeeting NIA-AA criteria, confirmed through Aβ+ PET.29,42 Stud-
ies defined preclinical AD as cognitively normal with Aβ+ status con-
firmed throughCSF or PET,35,44 except for one study that also included
participants who were cognitively impaired according to MMSE and
Montreal Cognitive Assessment (MoCA) but not with MCI and with
Aβ/tau- status confirmed through CSF.37 Studies imposed an inconsis-
tent range of exclusion criteria regarding conditions affecting the body
and eye, a list of which can be found in Supplementary Table S1.
3.2 Metrics and terminology
Six of the included studies mentioned pupillary dilation as being
included as part of their ophthalmological examination.32,37,40,41,43,44
Seven studies performed OCT-A measurements with the Optovue
RTVue XR Avanti (Optovue, Fremont, CA) with AngioVue software,
which operates using a split-spectrum amplitude decorrelation angiog-
raphy algorithm (SSADA). Six studies used the Zeiss Cirrus 5000 (Carl
Zeiss Meditech, Dublin, CA) with AngioPlex software, which uses an
optical microangiography (OMAG) approach. One study used the Top-
con DRI OCT Triton Plus (Topcon Medical Systems, Tokyo, Japan),
which employs OCT-A ratio analysis (OCTARA). It must also be










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































6 of 16 RIFAI ET AL.
noted that although 10 studies reported measurements automat-
ically calculated by OCT-A device software, three employed a
semi-automated method that involved non-standardized thresholding
protocols in ImageJ (https://imagej.nih.gov/ij/),36,37,41 and one used a
custom software.33
Due to the differences in OCT-A technology and boundaries for the
segmentationof retinal layers among the three types of devices, results
were not compared between studies that used different machines,
with the exception of the measurement of foveal avascular zone
(FAZ) area, which has been shown previously to be comparable across
platforms.46,47 Discrepancies considered, this review refers to mea-
surements taken from the layer referred to as superficial (retinal) vas-
cular plexus or superficial (retinal) capillary plexus as measurements in
the “superficial retinal layer” and measurements taken from the layer
referred to as deep (retinal) vascular plexus or deep (retinal) capil-
lary plexus as measurements in the “deep retinal layer” for simplicity,
although the boundaries for these layers may vary between studies
(Figure 1, Supplementary Table S2).47,48
Studies reported either area-based measurements (ie, total area
of vasculature per unit area), length-based measurements (ie, total
length of vasculature per unit area), or both. It must be noted that for
area-based measurements, larger vessels have a greater influence on
the measurement, whereas for length-based measurements, all ves-
sels influence the measurement equally. Thus length-based measure-
ments are more sensitive to changes in smaller capillaries.49 Supple-
mentary Table S2 lists the terminology used by each study and the cor-
responding definitions. Metrics that studies derived from the Optovue
machinewere: FAZ area; a densitymeasurement (area-based) referred
to as vessel density, vascular density, or microvascular density that will
herein be referred to as “vessel density”; vessel length density (length-
based, bespoke post-processing calculation); and flow index. Metrics
that studies derived from the Zeiss machine were: FAZ area; perfu-
sion density (area-based); and a density measurement (length-based)
referred to as vessel density or vascular density, which will herein be
referred to as “vessel density.” Metrics that studies derived from the
Topconmachinewere: a densitymeasurement (area-based) referred to
as capillary density that will herein be referred to as “vessel density.” It
is important to note that vessel density calculated with an Optovue or
Topconmachine is area-based, whereas for Zeissmachines, vessel den-
sity is length-based and perfusion density is the area-basedmetric.
OCT-A measurements were taken from regions (eg, foveal,
parafoveal, perifoveal, peripapillary, whole en face) within the super-
ficial and deep layers of the macula and the superficial and radial
peripapillary capillary layers of the optic disc (also known as the optic
nerve head), although fields of view and boundaries used to measure
these regions were not standardized, thereby limiting opportunities
to compare results among studies (Figure 1; Supplementary Tables
S2-3). Generally, the parafovea is defined as the annular area imme-
diately surrounding the foveal avascular zone, whereas the perifovea
is defined as the annular area surrounding the parafovea. The peri-
papillary region is generally defined as the annular area surrounding
the optic nerve head. Although some studies do not explicitly name
these areas as such, for example, 3-mm ring instead of parafovea,39
this review refers to these measurements using the aforementioned
terminology for simplicity. Whole density measurements include
both the FAZ and its surrounding area and are either taken from a
standardized circular region of interest or from the whole field of view
encompassed by the square en face image, depending on the study
(Figure 1).
3.3 FAZ area
FAZ area measured in square millimeters (mm2) was the most com-
monly included OCT-A measurement across the studies; of the 14
studies included, 10 published results featuring FAZ area differences
between case and control groups. Meta-analysis revealed an increase
in FAZ area in AD (mean difference [MD], 0.07 mm2; 95% CI, −0.00 to
0.13; Z, P = 0.06) with significant heterogeneity among studies (χ2, P
< 0.001) (Figure 2). Heterogeneity was still present when only stud-
ies using an Optovue machine were analyzed together (χ2, P < 0.001),
although in this analysis, there was a significant increase in FAZ area
in the AD group (MD, 0.11 mm2; 95% CI, 0.02 to 0.19; Z, P < 0.01)
(Supplementary Figure S2). Significant increases were found individ-
ually by Bulut et al. (MD, 0.14mm2; P< 0.05),Wu et al. (MD, 0.18mm2;
P < 0.05), and Zabel et al. (MD, 0.11 mm2; P < 0.001), studies which
had an older average AD participant age (74.2 ± 7.6 years, 69.9 ± 6.4
years, and 74.1 ± 5.9 years, respectively), and used Optovue machines
(Tables 1,2). By contrast, no evidence of significant differences in FAZ
area between participants with AD and controls was found by den
Haanet al. (MD,−0.02mm2;P>0.05), Lahmeet al., (MD, 0.00mm2;P>
0.05), and Yoon et al. (MD, 0.00 mm2; P > 0.05). These are studies that
had a younger average age for participants with AD (65.4 ± 8.1 years,
68.0 ± 9.3 years, and 72.8 ± 7.7 years, respectively), and of which two
used the Zeiss machine (Tables 1,2). Studies where participants were
age-matched,31,34,38 where agewas adjusted for,32,39 or where neither
was performed40 do not appear to segregate clearly with either signif-
icant or non-significant results, in the present and following sections.
For MCI, four studies provided measurements, of which Criscuolo
et al. (MD, 0.09mm2; P<0.001) andWuet al. (MD, 0.11mm2; P<0.05)
found a significant increase in MCI, whereas Yoon et al. (MD, −0.01
mm2; P > 0.05) and Zhang et al. (MD, −0.02 mm2; P > 0.05) found
no evidence of a significant difference compared to controls (Table 2).
Meta-analysis (MD,0.05mm2; 95%CI,−0.02 to0.11, Z,P=0.14) found
significant heterogeneity among these studies (χ2, P = 0.0002) (Fig-
ure 2). Of these, Wu et al. (MD, 0.07 mm2; significance not described)
and Yoon et al. (MD, 0.01 mm2; P > 0.05) included FAZ measurements
for both AD and MCI (MD, 0.04 mm2; 95% CI, −0.02 to 0.10; Z, P =
0.16) with no significant heterogeneity between them (χ2, P = 0.08).
For preclinical AD, two studies provided measurements for preclinical
AD (MD, 0.04 mm2; 95% CI, −0.05 to 0.13; Z, P = 0.35) with signifi-
cant heterogeneity between them (χ2, P = 0.008), of which O’Bryhim
et al. founda significant increase inFAZarea inpreclinicalAD (MD,0.08
mm2; P < 0.01) and van de Kreeke et al. found no evidence of a differ-
ence between preclinical AD and control groups (MD, 0.00 mm2; P >
0.05) (Figure 2; Table 2).
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F IGURE 1 Regionsmeasured for perfusion or vessel density by included studies compared to the Early Treatment Diabetic Retinopathy Study
(ETDRS) grid. A) Illustration of the fundus showing the location of themacula (blue) and optic disc (green) whereOCT-A scans are commonly
acquired and an ETDRS grid to compare with B. B)Macular (blue) regions and optic disc (green) regionsmeasured in each study. * indicates studies
that used anOptovuemachine, † indicates studies that used a Zeiss machine, and ‡ indicates studies that used a Topconmachine. A dotted overlay
indicates whole measurements. Dashed lines indicate the use of a regional boundary inconsistent with those of the ETDRS grid. A dotted line
indicates that boundarymeasurements were not described (Bulut et al.). A striped center indicates that FAZ area was subtracted from the outer
regions to calculate the boundary. C) A diagram of the anatomical layers of the retina with drawn vascular plexuses in red, currently used and
proposed 4-layer OCT-A segmentation based onmicrovasculature (adapted fromCampbell et al. with information fromMunk et al.47,48).
Automatic segmentation of superficial and deep layers byOptovue, Zeiss, and TopconOCT-Amachines are shown in red, green, and black
respectively. DCP, deep capillary plexus; DVC, deep vascular complex; GCL, ganglion cell layer; ICP, intermediate capillary plexus; INL, inner
nuclear layer; IPL, inner plexiform layer; NFL, nerve fiber layer; ONL, outer nuclear layer; OPL, outer plexiform layer; PR, photoreceptor layers;
RPC, radial peripapillary capillaries; RPCP, radial peripapillary capillary plexus; RPE, retinal pigment epithelium; S, superficial; SCP, superficial
capillary plexus; SVC, superficial vascular complex; SVP, superficial vascular plexus.
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F IGURE 2 Meta-analysis of foveal avascular zone (FAZ) measurements (mm2) for Alzheimer’s disease (AD), mild cognitive impairment (MCI),
and preclinical AD (preAD) participants versus controls (C) and AD versusMCI.Mean and standard deviation (SD) are included, with 95%
confidence intervals (CIs), heterogeneity scores, and overall effect in an inverse variance (IV) random effects model. The green square size
represents the weight attributed to each study based on relative sample size.N.B. Results from van de Kreeke et al. are unadjusted and were obtained
through personal correspondence with authors.
3.4 Density measurements in the superficial
retinal layer
Density (%) measurements were taken from a diverse range of reti-
nal areas and layers across studies resulting in limited opportunities
for direct comparison (Figure 1, Supplementary Table S2). Studies
were therefore compared only in groups that used the same machine
and software, as it has been shown that vessel density measurements
from different machines are not equivalent.46,50 The most commonly
characterized layer of the retina across the included studies was the
superficial layer, for which the most popular measurement was in the
parafoveal region. This included three Optovue studies of which Bulut
et al. (MD, −3.16%; P < 0.05) and Lahme et al. (MD, −2.62%; P < 0.01)
independently found a significant decrease in superficial parafoveal
vessel density in AD compared to controls (Table 2). Wu et al. (MD,
−0.91%; P > 0.05) found no evidence of a significant difference in
vessel density in the whole parafovea but when divided into sectors,
did find a significant decrease in the superior sector (MD, −1.69%; P
< 0.05). Meta-analysis revealed no significant heterogeneity between
studies (χ2, P = 0.24) and a significant overall effect of AD on superfi-
cial parafoveal vessel density (MD,−2.10%; 95%CI,−3.42 to−0.77; Z,
P = 0.002) (Figure 3). Five Zeiss studies could not be compared quan-
titatively due to differences in metrics and calculation methods. Of
these, Jiang et al. (fractal analysis: MD, not described; P < 0.05) and
Yoon et al. (vessel density: MD, −1.2%; P < 0.01; perfusion density:
−0.02%; P< 0.01) independently found a significant decrease in super-
ficial parafoveal vessel density in AD, whereas den Haan et al. (vessel
density: MD, −0.1%; P > 0.05) and Querques et al. (perfusion density:
MD, −0.26%; P > 0.05) found no evidence of a significant difference
(Table 2).
Two studies using Optovue provided a measurement for MCI par-
ticipants; Zhang et al. found a significant decrease in vessel density
in MCI compared to controls (MD, −3.83%; P < 0.05), whereas Wu
et al. found no evidence of a significant difference (MD, −0.10%;
RIFAI ET AL. 9 of 16
TABLE 2 Direction of effects reported in the included studies using optical coherence tomography angiography (OCT-A) to examine retinal



















Bulut et al. ↑AD ↓AD - ↓AD - - - -
Criscuolo et al. ↑ aMCI - - ↓ aMCI - ↓ aMCI - ↓ aMCI
Lahme et al. ∼AD ↓AD - ↓AD ∼AD ∼AD ∼AD ↓AD
O’Bryhim et al. ↑ preAD - - - - - - -
Wu et al. ↑AD ↑MCI ∼AD∼MCI ∼AD∼MCI - ↓AD ↓MCI - - -
Zabel et al. ↑AD n.d. n.d. ∼AD - ↓AD ∼AD ∼AD
Zhang et al. ∼aMCI/eAD ↓ aMCI/eAD - - ∼aMCI/eAD - ∼aMCI/eAD -




















denHaan et al. ∼AD ∼AD† ∼AD† - - - - -
Jiang et al. - ↓AD∼MCI† - - ↓AD∼MCI† - - -
Querques et al. - ∼AD∼MCI‡ ∼AD∼MCI‡ - ∼AD∼MCI‡ - - -
Sadda et al. - - - ∼preAD† - ∼preAD† - -
van de Kreeke
et al.
∼preAD ↑ preAD† ↑ preAD† - - - - -
Yoon et al. ∼AD∼MCI ↓AD∼MCI†/‡ - ↓AD∼MCI†/‡ - - - -

















Lee et al. - - - - - - - ∼ADC
Measurements that were included in at least 3 studies are shown, divided between studies using the Optovue and the Zeiss machines.N.B. Due to differences
in machines and software, measurements are not comparable between machines. ↑ indicates evidence of a significant increase in the case group compared to
the control group, ↓ indicates a significant decrease, and ∼ indicates no evidence of a significant difference. † indicates that vessel density was measured
and ‡ indicates that perfusion density was measured in studies using the Zeiss machine. N.d. indicates that a measurement of this type was mentioned, but
the effectwas not described. Abbreviations: AD, Alzheimer’s disease; ADCI, Alzheimer’s disease-related cognitive impairment; aMCI, amnesticmild cognitive
impairment; eAD, earlyAlzheimer’s disease; FAZ, foveal avascular zone;MCI,mild cognitive impairment; PD, perfusiondensity; preAD, preclinicalAlzheimer’s
disease; RPC, radial peripapillary capillaries; VD, vessel density.
P > 0.05). Meta-analysis revealed significant heterogeneity (χ2, P =
0.04) between these two studies (MD,−1.68%; 95% CI,−5.30 to 1.93;
Z, P = 0.36); this comparison should be considered with caution, as
Zhang et al. used a calculation protocolwith external software (ImageJ,
an open-source image-processing program) in addition to AngioVue
software, which may affect the equivalence of their measurements to
those reported by other studies. Three studies using Zeiss also pro-
vided ameasurement forMCI participants, of which Jiang et al. (fractal
analysis: MD, not described; P > 0.05) and Querques et al. (perfusion
density: MD, 1.21%; P > 0.05) found no evidence of a significant dif-
ference between MCI and control participants. Of interest, Yoon et al.
found a significant decrease in AD compared to MCI (vessel density:
MD, −1.3%; P < 0.01; perfusion density: MD, −0.02%; P < 0.01). Simi-
larly, one studyusingZeiss found that superficial parafoveal vessel den-
sity was significantly increased in preclinical AD compared to control
participants (vessel density: MD, 0.81%; P< 0.001).44
Another common superficial vessel density measurement was
whole (en face) vessel density, which includes the FAZ (Figure 3). Two
studies using Optovue, Bulut et al. (MD, −3.17%; P < 0.01) and Lahme
et al. (MD, −2.87%; P < 0.001), independently found this measure to
be significantly decreased in AD compared to controls, whereas Zabel
et al. found no evidence of a significant difference (MD, −0.73%; P >
0.05) (Table 2). Meta-analysis of three Optovue studies revealed no
significant heterogeneity (χ2, P = 0.09) and a significant overall effect
of AD for this metric (MD, −2.21%; 95% CI, −3.75 to −0.67; Z, P =
0.005). This comparison should be regarded with a degree of caution,
however, as there were differences in the field of view from which
these measurements were obtained. As for MCI, Criscuolo et al. found
a significant decrease in whole vessel density in MCI compared to
controls (MD, −3.14%; P < 0.01). The study of Yoon et al. using Zeiss
found, similar to their parafoveal measurements, a significant decrease
in AD compared to MCI (vessel density: MD, −1.3%; P < 0.01; perfu-
sion density: MD, −0.019%; P < 0.01) and a significant decrease in AD
compared to controls (vessel density: MD, −1.2%; P < 0.05; perfusion
density:MD,−0.018%;P<0.01). A smaller study using a Zeissmachine
looked at a preclinical AD group that included both cognitively normal
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F IGURE 3 Meta-analysis of superficial parafoveal andwhole vessel density (%) for participants with Alzheimer’s disease (AD) and participants
withmild cognitive impairment (MCI) versus controls (C). Mean and standard deviation (SD) are included, with 95% confidence intervals (CIs),
heterogeneity scores, and overall effect in an inverse variance (IV) random effects model. The green square size represents the weight attributed
to each study based on relative sample size.
biomarker-positive (Aβ or tau), and cognitively impaired
(MMSE/MoCA but not MCI) biomarker-negative, and found no
evidence of a significant difference in superficial whole vessel density
between their groups (vessel density: MD, 1%; P> 0.05).37
Superficial foveal vessel density measurements were reported by
studies that used Optovue machines, of which Bulut et al. did (MD,
−5.76%; P< 0.01) and Lahme et al. did not (MD,−1.66%; P> 0.05) find
evidence of a significant difference in AD compared to controls. Super-
ficial perifoveal density measurements were reported in four studies
(Table 2). One study using Optovue (AD vs C: MD, −0.84%; P > 0.05;
MCI vs C: MD, 0.36%; P > 0.05) and one study using Zeiss (perfusion
density: AD vs C:MD, 0.12%; P> 0.05; MCI vs C:MD, 0.39%; P> 0.05)
found no evidence of a significant difference between AD or MCI and
controls.36,38 Similarly, den Haan et al. found no evidence of a signif-
icant difference between AD and controls (MD, −0.4%; P > 0.05). Of
interest, van de Kreeke et al. found a significant increase in superfi-
cial perifoveal vessel density in their preclinical AD group compared to
their control group (MD, 0.50%; P< 0.05).
3.5 Density measurements in the deep retinal
layer, choriocapillaris, and choroid
The most commonly reported density measurement for the deep reti-
nal layer was in the parafoveal region (Table 2). Both Wu et al. (MD,
−9.18%; P < 0.001) and Jiang et al. (vessel density: MD, not described;
P < 0.05) reported a significant decrease in vessel density in this
region in AD compared to controls, whereas neither Lahme et al.
(MD, −0.41%; P > 0.05) nor Querques et al. (MD, −1.99%; P > 0.05)
found evidence of a significant difference in vessel density and perfu-
sion density, respectively. Regarding MCI, Wu et al. reported a signif-
icant decrease in vessel density compared to controls (MD, −4.19%;
P < 0.001), whereas Jiang et al. (vessel density: MD, not described;
P > 0.05), Querques et al. (perfusion density: MD, −0.72%; P > 0.05),
and Zhang et al. (vessel density: MD, −0.54%; P > 0.05) did not find
evidence of a significant difference. Wu et al. also found a significant
decrease in AD compared to MCI (MD, −4.99%; P < 0.001). Other
regionsmeasured in this layer included the fovea, perifovea, andwhole
measurements. Lahme et al. provided a foveal vessel density mea-
surement, which was not found to be significantly different between
AD and controls (MD, 1.89%; P > 0.05). Wu et al. reported a peri-
foveal vessel density measurement and found deep perifoveal vessel
density to be significantly decreased in both AD (MD, −7.64%; P <
0.001) and MCI (MD, −2.25%; P < 0.001) compared to controls, as
well as in AD compared to MCI (MD, −5.39%; P < 0.001). Querques
et al. included a perifoveal perfusion density measurement, which was
not found to be significantly different between AD (MD, −0.46%;
P > 0.05) or MCI (MD, −0.33%; P > 0.05) and controls. Deep whole
measurements of vessel density from Zabel et al. found a signifi-
cant decrease in AD compared to controls (MD, −5.51%; P < 0.001),
whereas Lahme et al. found no evidence of a significant difference
(MD,−1.37%; P> 0.05). Criscuolo et al. found a significant decrease in
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deep whole vessel density in MCI compared to controls (MD, −5.48%;
P < 0.001), whereas Sadda et al. found no evidence of a significant dif-
ference between preclinical AD and controls (MD,−1%, P> 0.05).
Querques et al. and Sadda et al. (two studies using Zeiss) included
measurements in other layers such as the choriocapillaris and choroid.
Querques et al. found no evidence of a significant difference in perfu-
sion density of the choriocapillaris (perfusion density (3 x 3mm): AD vs
C: MD, 0.05%; P > 0.05; MCI vs C: MD, −0.22%; P > 0.05; AD vs MCI:
MD, 0.27%; P > 0.05) or choroid (perfusion density (3 x 3 mm): AD vs
C: MD, -0.16%; P > 0.05; MCI vs C: 0.11%; P > 0.05; AD vs MCI: MD,
−0.27%; P > 0.05) between AD, MCI, and controls. Sadda et al. found
no evidence of a significant difference in the vessel density of the chori-
ocapillaris in the macular region between preclinical AD and controls
(MD,−1%; P> 0.05).
3.6 Density measurements in the optic disc
region
Three studies using Optovue provided measurements of vessel den-
sity for the peripapillary region in the radial peripapillary capillary
layer of the optic disc, two of which compared participants with AD
and controls,34,40 and one of which compared participants with MCI
to controls.41 None of these found evidence of significant differences
between case and control groups (Lahme:MD, -1.94%; P> 0.05; Zabel:
MD, 1.05%; P> 0.05; Zhang: vessel density: MD, -0.27%; P> 0.05; ves-
sel length density: MD, -0.84%; P> 0.05). Two studies provided a mea-
surement of the peripapillary region in the superficial layer. One study
found no evidence of a significant difference between MCI and con-
trols (vessel density: MD, -1.84%; P > 0.05; vessel length density: MD,
-0.58%; P > 0.05).41 The other study provided this measurement for
preclinical AD in the superficial layer and did find evidence of a signif-
icant difference between preclinical AD and control participants (MD,
0.83%; P< 0.05).44
Four studies provided a whole vessel density measurement in the
radial peripapillary capillary layer. Lahme et al. found a significant
decrease in whole vessel density in AD compared to controls (MD, -
2.32%; P < 0.05) in this region, whereas Zabel et al. found no evidence
of a difference (MD, 1.64%;P>0.05). Criscuolo et al. found a significant
decrease in whole vessel density in MCI compared to controls (MD, -
2.04%; P< 0.05). One study, which compared an ADCI group including
bothADandMCIparticipants to controls, foundnoevidenceof a signif-
icant difference in whole vessel density between their ADCI group and
control participants in any of the measured quadrants (superior: MD,
0.99%; P > 0.05; inferior: MD, 3.76%; P > 0.05; temporal: MD, -2.69%;
P> 0.05; nasal: -0.82%; P> 0.05).42
3.7 Blood flow velocity measurements
Two studies using Optovue included unitless metrics that indicate
blood flow velocity. Bulut et al. reported an outer retinal (MD, -0.01;
P > 0.05) and a choroidal (MD, -0.01; P > 0.05) flow (index) rate, which
are described to be lower, although not significantly, in AD versus con-
trols. Zhang et al. reported a significantly lower adjusted flow index in
the parafoveal superficial capillary plexus in aMCI/eAD compared to
controls (MD, -0.031; P < 0.05). Studies involving preclinical AD par-
ticipants did not report a flow indexmeasurement.
4 DISCUSSION
Although many studies support the correlation of blood and CSF
biomarkers with amyloid pathology and dementia diagnosis, retinal
imaging is less invasive and could be more widely applicable as a
screening tool if validated.51,52 Thus the possibility that OCT-A could
be used for preclinical or clinical dementia diagnosis is exciting, as
it would be an efficient and economical method for determining
where there is need for early intervention. Informal comparisons and
meta-analyses in the current review reveal that FAZ area, superfi-
cial parafoveal, and whole vessel density may have the potential to
serve as indicators of AD; effect sizes of significant findings in indi-
vidual studies are very large for FAZ area (Cohen’s d = 1.01 to 2.39)
and medium to large for superficial parafoveal (Cohen’s d = 0.67 to
0.81) and whole vessel densities (Cohen’s d= 0.61 to 0.89), which sug-
gests that the differences are non-trivial.53 However, the significant
heterogeneity among studies, which may be attributed to several fac-
tors discussed later, prevents an inference from being made at present
regarding their clinical utility (Figure 4). In addition, it will be impor-
tant for this technique to be sufficiently sensitive to pick up changes
that occur in preclinical AD or MCI to provide opportunities for early
intervention.Meta-analyses in this study reveal no evidence of a signif-
icant difference between preclinical AD or MCI and controls for these
measures, although such analyses are limited, and retinal microvascu-
lar changes that occur in preclinical AD or MCI may become clearer
through increased standardization.
A major obstacle preventing the comparison of studies was the
different types of OCT-A machines used to perform measurements;
different algorithms are used to reconstruct the images, and differ-
ent terminology is employed between Optovue, Zeiss, and Topcon.
This is further compounded by differences in retinal layer segmen-
tation, leading to uncomparable vessel density calculations46,47,50,54
(Figure1,SupplementaryTable S2). Furthermore, one studyhas shown
that different AngioVue software updates generate significantly dif-
ferent results due to a change in segmentation boundaries calculated
between software versions.55 In order to be able to confidently com-
pare and meta-analyze measurements obtained from OCT-A for an
overall effect of any disease on these metrics, it is crucially impor-
tant to standardize the boundaries of the retinal layers being mea-
sured, the language that is used to describe them, and the metrics
that are subsequently derived.48 Ideally, those who are using different
machines shoulddescribe in clear detail the retinal layers that arebeing
investigated, the boundaries that define them, how these compare to
those calculated by other machines, and their current software ver-
sion. It appears that FAZ area differences tend to be more significant
between case and control groups in studies that featuredOptovue, and
12 of 16 RIFAI ET AL.
F IGURE 4 Recommendations for standardization of studies using optical coherence tomography angiography (OCT-A) to detect changes in
the retinal microvasculature in preclinical Alzheimer’s disease (AD), mild cognitive impairment (MCI), and Alzheimer’s disease (AD). Abbreviations:
Aβ+, amyloid beta-positive; ETDRS, Early Treatment Diabetic Retinopathy Study;MMSE,MiniMental State Examination;MoCA,Montreal
Cognitive Assessment; NIA-AA, National Institute on Aging and Alzheimer’s Association; NINCDS-ADRDA, National Institute of Neurological,
Communicative Disorders and Stroke-Alzheimer Disease and Related Disorders Association; STROBE, Strengthening the Reporting of
Observational Studies in Epidemiology.
a significant overall effect of AD on superficial parafoveal and whole
vessel densitywas found in themeta-analysis of studies usingOptovue.
However, this tendency must be considered with caution as there was
heterogeneity in parafoveal boundaries and participant populations,
and the numbers of participants in the studies were small. Further-
more, although some studies reported automated calculations, oth-
ers included semi-automated procedures that involved image analysis
with additional software; this is another source of heterogeneity, but
one that could be reduced by establishing a standardized protocol for
calculating certain density metrics, a set of inter-machine correction
factors, or perhaps the development of a platform-independent soft-
ware, such as that which has been developed for spectral-domain
OCT (SD-OCT).56 Using a machine-learning approach such as deep
learning may be an option for circumventing the limitations of cur-
rent OCT-A algorithms, as classifiers of disease stage can be learned
based on images only and without the need for post-processing
and quantification.57,58 However, in the field of neurodegenerative
research, it may be challenging to collect the sizeable volume of clinical
data needed to achieve an acceptable level ofmachine-learning perfor-
mance, as well as to discern which discriminating features such a sys-
tem is utilizing in the classifying process.
Reaching a consensus regarding the boundaries that define areas
such as the fovea, parafovea, and perifovea in the macula and the peri-
papillary region of the optic disc, as well as fields of view (3 × 3 mm
vs 6 × 6 mm macula; 4.5 × 4.5 mm optic disc) used to image these
regions and whether to include the fovea or optic nerve head in the
center, would achieve further standardization. This could perhaps be
achieved in a manner similar to what was achieved with SD-OCT.59 At
present, studies contain different sets of measurements and discrep-
ancies in defined boundaries, which prevents conclusions from being
reached regarding the reproducibility of findings and the potential for
certain metrics to be used as biomarkers for different stages of dis-
ease (Supplementary Table S3). Going forward, it will be important
to establish a set of metrics with comprehensive descriptions recom-
mended for inclusion in studies featuring OCT-A so that the overall
effects of disease progression on vessel density in these regions can
be more readily discerned. One standard that could be used (and that
has been used by some of the included studies) is the Early Treatment
Diabetic Retinopathy Study (ETDRS) grid, which delineates nine sec-
tors in the macula: a centered circle with a 1 mm radius, an inner ring
1-3 mm from the center divided into four quadrants, and an outer ring
3-6mm from the center divided into four quadrants. These could serve
as standard boundaries for the fovea, parafovea, and perifovea, respec-
tively. Two studies included measurements for sectors within areas
such as the parafovea and perifovea and found changes specific to cer-
tain sectors, although the way that they were defined varied between
the studies, that is, superior, inferior, temporal, and nasal versus supe-
rior temporal, superior nasal, inferior temporal, and inferior nasal
(Figure 1).33,38,42 It is possible that changes occurring through the
dementia disease course are sector-specific and are consequently
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overlookedwhencalculations aremadeover larger areas. Thus itwould
be worthwhile to include measurements for individual sectors so that
any potential changes of this type are not disregarded. Along with this,
we recommend that OCT-A images are included in the studies, so that
differences between case and control groups may be visualized. Com-
parison images between case and control groups were included in only
seven of the studies reviewed.33–35,39,40,42,43
Another likely source of heterogeneity among the included stud-
ies is the diversity in participant populations. Although a number of
studies matched cases and controls based on age and sex or include
an age or sex adjustment, it is possible that differences in these fac-
tors contributed to some of the inconsistent results between stud-
ies, especially as FAZ area and vessel density have been found to
change with normal aging.60 For example, studies that found a signif-
icant enlargement of FAZ area in AD31,38,40 tended to have an older
average AD participant age than studies that did not, so it is possible
that these participants had more severe AD than those at a younger
age. With regard to sex, lower superficial vessel density was signifi-
cantly associated with male sex in a recent population-based study.61
It would be of value to include sex-stratified data in future studies in
order to determine whether certain findings are sex-specific, as well
as to reduce variation within groups so that calculations can be more
sensitive to smaller effect sizes. Furthermore, although the included
studies selectedparticipants basedonestablishedNIA-AAorNINCDS-
ADRDA diagnostic criteria, it is possible that an AD group could be
heterogeneous; for example, there may be differences in Aβ or tau
levels within the group, or other forms of dementia present instead of,
or alongside, AD thatmay act as confounding variables. Although some
studies excluded participants with other types of dementia, neurode-
generation, or neurological disease,31,36,38–40,42,43 others did notmake
mention of this. In addition, confirmation of AD through biomarker
testing was a diagnostic requirement for participants in only three
studies.32,40,42 It will be important to utilize biomarker levels as a
covariate and a requirement for comprehensive AD selection criteria,
since the NIA-AA research framework was recently revised to include
CSFand imagingbiomarkers.27 Thismaybe challenging, however,with-
out funding given their expense. Itmay also be helpful to includeMMSE
and MoCA scores as another metric for AD staging after diagnosis
using biomarkers.
How preclinical AD and MCI groups were defined varied consid-
erably among studies. Although two studies defined their preclinical
group as cognitively normal Aβ+,35,44 one study involved a preclini-
cal AD group that was referred to as the “AD group” and contained
both cognitively normal Aβ/tau+ participants and cognitively impaired
Aβ/tau- participants without MCI.37 Many studies included MCI par-
ticipants meeting NIA-AA or Petersen criteria, although one study of
the former type refers to both amnestic MCI and early stage AD and
combines them into one group.41 One study combined MCI partici-
pants andADparticipants into one group.42 These groupings appeared
to be heterogeneous, and future studies would benefit from further
standardization and stratification of groupings to investigate the reti-
nal changes occurring in the different stages preceding AD. The need
for this is accentuated by the possibility of a biphasic effect occur-
ring, whereby vessel density increases in preclinical AD or MCI and
decreases in AD, leading to mixed results across studies. Such a model
is supported by findings from van de Kreeke et al., where an increase
in vessel density was reported in cognitively normal Aβ+ participants
compared to controls. Thismay also occur in the progression fromMCI
to AD, as Yoon et al. found a decrease in vessel density in AD com-
pared to MCI. Thus standardization of participant characterization as
outlined by McKhann et al. is of the utmost importance to determine
whetherOCT-A is sufficiently sensitive to detect changes between dif-
ferent stages along the disease continuum.
Regarding the ophthalmological examination, pupillary dilation was
mentioned in only some of the included studies.31,32,35–37,40,41,43,44
Although pupillary dilation is not required to perform OCT-A, it is
important to consider whether this has an impact on image quality and
the ensuingmeasurements.We therefore recommend that whether or
not pupillary dilationwas performed prior toOCT-A imaging should be
explicitly mentioned when reporting a study. Further investigation is
now needed to reach a consensus on whether pupillary dilation should
be performed in future studies to yield consistent image quality and
potentially more reliable measurements, or whether undilated exam-
ination is sufficient, considering that scan quality has been shown to
improve with dilation.62 Furthermore, there were differences in the
decisions made across studies about whether to include one or both
eyes in analyses. Some studies chose one eye consistently, some chose
one eye randomly or based on best image quality, some averaged val-
ues for both eyes, and some included values for both eyes where pos-
sible but used a generalized estimating equation (GEE) correction to
account for sample size inflation. We recommend that details about
eye selection are clearly reported and that this is as consistent as pos-
sible among participants, as right and left eyes for a person may not
be interchangeable due to interocular asymmetry.63 Finally, ophthal-
mological confounders should be consideredwhere possible; for exam-
ple, axial length has been shown to impact both foveal avascular zone
area and superficial vessel density measurements, yet only two stud-
ies described a range of axial length measurements in their inclusion
criteria31,38,64 (Supplementary Table S1). Other studies chose to sta-
tistically adjust for potential confounders such as age and spherical
equivalent.32,35,39,42–44
External sources of heterogeneity notwithstanding, it must also be
noted that the metrics discussed in this review have inherent limita-
tions that may contribute to the inconsistent results observed across
the literature. For example, FAZ area measurements are limited to a
fewdeep layers of capillaries of the foveal pit, and thus the detection of
disease-associated changes may only be possible within a certain win-
dow duringwhich these particular layers are affected.65 It is important
to note that the FAZ area does not take into account the ganglion cell
layer, which is known to be impacted by neurodegeneration.66 Mea-
suring vessel density of the parafovea and perifovea can provide some
of this information to which the FAZ area metric may be less sensi-
tive, although vessel density measurements may also be influenced by
noise in the image, or variable anatomic features, and are thus depen-
dent upon the calculationmethod used.67 It may also be advantageous
to explore the use of more peripheral retinal metrics, which may be
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less affected by the above limitations as well as any central media
opacity. However, we acknowledge that this could require machines
with larger fields of view or different gaze positions for the participant,
and the imagesmaybemore challenging to segment accurately, correct
for distortion, and analyze.65 In any case, we recommend using mul-
tiple metrics to create a more holistic picture of the retinal microvas-
culature, and we stress that obtaining good quality images with clear
ocular media is criticial for all metrics. Furthermore, there can be nat-
ural variability of these parameters in healthy adults, and thus we
emphasize the need for longitudinal monitoring of the same partici-
pants to determine how individuals are changing over time.68,69 Finally,
further consideration must be made regarding the appropriateness
of measuring computed blood flow velocity using OCT-A rather than
methods that show live blood flow metrics, such as adaptive optics
scanning laser ophthalmoscope (AOSLO) imaging, adaptive optics (AO)
OCT-A, the retinal functional imager (RFI) system, or laser speckle
flowgraphy (LSFG), asOCT-Ameasurementsmay be picking up projec-
tion artifacts.70,71
Finally, although study design could often be inferred from the study
descriptions presented in each of the articles we reviewed, the lan-
guage used to describe study designs varied. It is therefore recom-
mended that reporting guidelines, such as those of Strengthening the
Reporting of Observational Studies in Epidemiology (STROBE), are
followed to ensure clear and comprehensive descriptions of study
design.72 Sample sizes in most of the studies were relatively small
(though we recognize the challenges involved in conducting studies
with these particular participant groups), so it will be important to con-
duct similar investigations with larger populations to increase the sta-
tistical powerwhen investigating associations betweenOCT-Ametrics
and AD. In addition, a major advantage of standardization would be
inter-study comparability, which can be used to overcome the limita-
tions of small sample sizes in individual studies. Furthermore, a consis-
tent approach would also benefit research into associations of OCT-A
metrics with biomarkers derived from other neuroimaging techniques,
such asMRI and PET, as better understanding of how these techniques
can be used in conjunctionwith each othermay allow for improved risk
assessment. Finally, no longitudinal studies matching the inclusion and
exclusion criteria were found in our literature search. Because OCT-A
is still a relatively new technology, this may be unsurprising, but it is
vital for future work to include follow-up measurements on the same
participant populations while remaining wary of the aforementioned
sources of variance. This way, changes in these measurements can be
effectively tracked over time in order to gain insight into the dynamics
of the retinal microvasculature with disease progression.
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